All In Biotech

Drug Trial Radar · NCT06048588

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

A Phase I/IIa Trial to Evaluate the Safety, Tolerability, PK, and Preliminary Efficacy of Single and Multiple Ascending Doses of YN001 in Healthy Subjects and Multiple Ascending Doses of YN001 in Patient With Coronary Atherosclerosis

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

Oct 8, 2023

Primary completion

Apr 27, 2025

Study completion Apr 27, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study consists of two parts. The SAD and MAD of part I are a randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult subjects. The MAD expansion cohort of part I is single arm and multipal ascending dose in heallthy subjects. Part II (phase Ib/IIa) is a multicenter, randomized, controlled, open label, multiple ascending dose study in patients with coronary atherosclerosis.

Conditions

  • Atherosclerotic Cardiovascular Disease

Interventions

  • YN001Drug

    In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.

  • Placebo for YN001Drug

    The injection solution to mimic the YN001

  • rosuvastatin calcium tabletsDrug

    In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I: The safety and tolerability of YN001 in healthy subjects.Time frame: Up to 29 days
  2. Part I: Maximum plasma concentration(Cmax) of YN001Time frame: Up to 168 hours of post initiation of last dose
  3. Part I: Time of maximum concentration (Tmax) of YN001Time frame: Up to 168 hours of post initiation of last dose
  4. Part I: Elimination half-life (t1/2) of YN001Time frame: Up to 168 hours of post initiation of last dose
  5. Part I: Area under the plasma concentration-time curve from time 0 to the collection time point of the last measurable concentration (AUC0-t) of YN001Time frame: Up to 168 hours of post initiation of last dose
  6. Part II: The safety and tolerability of intravenously administered YN001 in patients with coronary atherosclerosis.Time frame: Up to 29 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University first hospital

    Beijing, Beijing Municipality, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • First Hospital of Jilin University

    Changchun, Jilin, China

  • Renji Hospital Shanghai Jiaotong Unv. school of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.